(:MRTX)

Jan 10, 2024 07:00 am ET
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy.
Nov 30, 2023 10:37 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, HES, SIX, MIRO
NEW YORK, Nov. 30, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 15, 2023 12:41 pm ET
Moore Kuehn Encourages PCTI, MRTX, CSTR, and BBAI Investors to Contact Law Firm
NEW YORK, Nov. 15, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Nov 10, 2023 06:30 am ET
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Fo
SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the Company has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy.
Nov 09, 2023 08:44 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, GAN
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Mirati Therapeutics, Inc. (NASDAQ:...
Nov 08, 2023 02:03 pm ET
MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mirati Therapeutics, Inc. (NasdaqGS: MRTX) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Mirati will receive $58.00 in cash for each share of Mirati that they own as well as one non-tradeable Contingent Value Right per Mirati share, entitling its holder to receive a one-time potential payment of $12.00 in cash upon acceptance by U.S. FDA of a new drug application for MRTX1719 for the
Nov 06, 2023 07:00 am ET
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.
Nov 04, 2023 12:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SLGC, SP, MRTX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SomaLogic, Inc. (NASDAQ: SLGC)’s sale...
Nov 03, 2023 05:40 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SIX, MRTX, FAZE, TGH
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2023 ISS Securities Class Action Services Report and...
Nov 03, 2023 05:19 pm ET
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
SAN DIEGO and ZUG, Switzerland, Nov. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for KRAZATI® (adagrasib) as a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.
Nov 02, 2023 07:30 am ET
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology...
Oct 31, 2023 04:14 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, PCTI, MRTX
NEW YORK, Oct. 31, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 27, 2023 06:00 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – MRTX, FAZE, HES, TGH
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2023 ISS Securities Class Action Services Report and headquartered...
Oct 26, 2023 01:23 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PNT, MRTX, ORTX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: POINT Biopharma Global, Inc. (NASDAQ:...
Oct 26, 2023 12:29 pm ET
Moore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law Firm
NEW YORK, Oct. 26, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
Oct 21, 2023 09:28 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, MRTX, ICPT
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SP® Plus Corporation (NASDAQ: SP)’s...
Oct 20, 2023 09:01 am ET
MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb
The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Mirati Therapeutics, Inc. (Nasdaq: MRTX) (“Mirati”) to Bristol Myers Squibb (“Bristol Myers”) for $58.00 per share in cash, plus a contingent value right...
Oct 17, 2023 07:59 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, OLK, ORTX, MRTX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SP® Plus Corporation (NASDAQ: SP)’s...
Oct 17, 2023 06:03 pm ET
Moore Kuehn Encourages SP, ORTX, MRTX, and SRT Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Oct 17, 2023 04:00 pm ET
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
SAN DIEGO, Oct. 17, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.®  (NASDAQ: MRTX), a commercial stage biotechnology company, today announced updated results from the KRYSTAL-7 Phase 2 study evaluating adagrasib combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation at the European Society of Medical Oncology Congress (ESMO) 2023. These data demonstrate a manageable safety profile and early signs of durability of adagrasib in combination with a checkpoint inhibitor in the first-line NSCLC setting.
Oct 16, 2023 06:21 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNSL, PCTI, SP, MRTX
NEW YORK, Oct. 16, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 16, 2023 02:59 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Oct 11, 2023 07:08 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, NWLI, PWFL
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Mirati Therapeutics, Inc. (NASDAQ:...
Oct 10, 2023 12:37 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWLI, MRTX, SLGC, PNT
NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Oct 09, 2023 05:00 pm ET
MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mirati Therapeutics, Inc. (NasdaqGS: MRTX) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Mirati will receive $58.00 in cash for each share of Mirati that they own as well as one non-tradeable Contingent Value Right per Mirati share, entitling its holder to receive a one-time potential payment of $12.00 in cash upon acceptance by U.S. FDA of a new drug application for MRTX1719 for the
Oct 09, 2023 10:08 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.® (Nasdaq - MRTX), LiveVox Holdings, Inc. (Nasdaq - LVOX), SP® Plus Corporation (Nasda
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Oct 09, 2023 07:25 am ET
Shareholder Alert: Ademi LLP investigates whether Mirati Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myers Squibb
MILWAUKEE, Oct. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating Mirati (Nasdaq: MRTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myers Squibb.
Oct 08, 2023 08:49 pm ET
MRTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mirati Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mirati Therapeutics, Inc. (NASDAQ: MRTX) to Bristol Myers Squibb for $58.00 per share in cash is fair to Mirati shareholders. Additionally, Mirati shareholders will also receive one non-tradeable Contingent Value Right per Mirati share, entitling its holder to receive a one-time potential payment of $12.00 in cash upon acceptance by U.S. FDA of a new drug application for MRTX1719 for the treatment of either locally advanced or metastatic NSCLC in patients who have received no more than two prior lines of system
Oct 08, 2023 06:02 pm ET
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Bristol Myers Squibb (NYSE: BMY) and Mirati Therapeutics, Inc.® (NASDAQ: MRTX) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion. Mirati stockholders will also receive one non-tradeable Contingent Value Right (CVR) for each Mirati share held, potentially worth $12.00 per share in cash, representing an additional $1.0 billion of value opportunity. The transaction was unanimously approved by both the Bristol Myers Squibb and the M
Oct 08, 2023 05:16 pm ET
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Bristol Myers Squibb (NYSE: BMY) and Mirati Therapeutics, Inc.® (NASDAQ: MRTX) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion. Mirati stockholders will also receive one non-tradeable Contingent Value Right (CVR) for each Mirati share held, potentially worth $12.00 per share in cash, representing an additional $1.0 billion of value opportunity. The transaction was unanimously approved by both the Bristol Myers Squibb and the M
Sep 27, 2023 04:30 pm ET
Mirati To Present Updated Clinical Data at ESMO Congress 2023
Late-Breaking KRYSTAL-7 data demonstrates compelling efficacy and safety of adagrasib in combination with pembrolizumab in 1L NSCLC
Aug 02, 2023 05:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mirati Therapeutics, Inc. – MRTX
Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. (“Mirati” or the “Company”) (NASDAQ: MRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jul 27, 2023 03:31 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirati Therapeutics, Inc. - MRTX
Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. (“Mirati” or the “Company”) (NASDAQ: MRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jul 25, 2023 05:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirati Therapeutics, Inc. - MRTX
NEW YORK, July 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. ("Mirati" or the "Company") (NASDAQ: MRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 25, 2023 04:30 pm ET
Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023
SAN DIEGO, July 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates on August 8, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on August 8, company executives will provide company updates and review financial results.
Jul 21, 2023 07:56 am ET
Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation
SAN DIEGO and ZUG, Switzerland, July 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the Conditional Marketing Authorisation Application (MAA) for KRAZATI® (adagrasib) for treatment of patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC).
Jun 23, 2023 04:00 pm ET
Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.
Jun 20, 2023 08:00 am ET
Journal of Clinical Oncology Publishes Clinical Results of Adagrasib as a Targeted Treatment for KRASG12C-Mutated NSCLC with Untreated Central Nervous System (CNS) Metastases
Adagrasib is the first and only KRASG12C inhibitor to prospectively demonstrate intracranial (IC) activity in KRASG12C-mutated NSCLC with untreated CNS metastases 
Jun 01, 2023 04:30 pm ET
Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023
SAN DIEGO, June 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. P.T. / 11:40 a.m. E.T. David Meek, chief executive officer, will represent the company in a fireside chat at the conference.
May 30, 2023 04:00 pm ET
Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting
Data follows recent inclusion of Adagrasib in NCCN Guidelines for PDAC and CNS Cancers
May 24, 2023 04:01 pm ET
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO®
SAN DIEGO, May 24, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial-stage oncology company, today announced that the SAPPHIRE study did not meet its primary endpoint of overall survival at the final analysis. SAPPHIRE is a Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 versus docetaxel in patients with second or third line advanced non-squamous non-small cell lung cancer (NSQ-NSCLC) who progressed on prior therapy with chemotherapy and immune checkpoint inhibitor therapy. The company plans to disclose the study data at a future date
May 09, 2023 04:01 pm ET
Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates
SAN DIEGO, May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates.
May 08, 2023 08:30 am ET
Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies
SAN DIEGO and NASHVILLE, Tenn., May 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, and Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, today announced a strategic partnership aimed at increasing diversity in clinical study recruitment practices.
May 05, 2023 04:00 pm ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, May 5, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 2 new employees with a grant date of May 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Apr 27, 2023 04:30 pm ET
Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference
SAN DIEGO, April 27, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Bank of America Securities 2023 Health Care Conference on May 11 at 10:00 a.m. P.T. / 1:00 p.m. E.T. Ben Hickey, chief commercial officer, will represent the company in a fireside chat at the conference.
Apr 26, 2023 04:33 pm ET
Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors
Data demonstrates compelling clinical activity, highlights adagrasib potential as monotherapy in solid tumors
Apr 25, 2023 04:30 pm ET
Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023
SAN DIEGO, April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on May 9, company executives will provide company updates and review financial results.
Apr 03, 2023 04:00 pm ET
Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs
Preclinical data highlights MRTX0902 and MRTX1719 as potentially compelling targeted oncology treatment options
Feb 27, 2023 10:00 am ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Mirati Therapeutics, Inc. (MRTX) and Encourages Long-Term MRTX Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Mirati Therapeutics, Inc. (NASDAQ: MRTX) on behalf of the company’s long-term investors. The investigation seeks to determine whether Mirati has issued false and misleading statements and/or...
Feb 03, 2023 03:31 pm ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 4 new employees with a grant date of February 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Feb 01, 2023 03:30 pm ET
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
SAN DIEGO, Feb. 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate in two upcoming healthcare conferences.
Jan 19, 2023 04:00 pm ET
Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133
IND demonstrates Mirati's leadership in KRAS, representing the Company's third KRAS or KRAS-signaling program to enter clinical development
Jan 06, 2023 03:00 pm ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 6 new employees with a grant date of January 3, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Dec 22, 2022 03:30 pm ET
Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41st J.P. Morgan Annual Healthcare Conference, on January 9, 2023. David Meek, chief executive officer, will make a formal presentation, and answer questions about the Company at 9:00 a.m. P.T. / 12:00 p.m. E.T.
Dec 21, 2022 04:00 pm ET
Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib Wi
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for adagrasib (KRAZATITM) in combination with cetuximab in patients with KRASG12C-mutated advanced colorectal cancer (CRC) whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy.Journal publication marks second New England Journal of Medicine (NEJM) inclusion in 2022 for adagrasib.SAN DIEGO, Dec. 21, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today that the FDA has granted BTD to adagrasib in combination with cetuximab in patients
Dec 13, 2022 03:00 pm ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 13, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 11 new employees with a grant date of December 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Dec 12, 2022 05:41 pm ET
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) w
SAN DIEGO, Dec. 12, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI™ (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Dec 05, 2022 05:05 pm ET
Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRASG12C mutationFindings will be presented on December 7 at the 2022 ESMO Immuno-Oncology Annual Congress, as an oral presentation from 2:05 p.m.-2:15 p.m. CET / 8:05 a.m.-8:15 a.m. ET (Presentation #LBA4) during the "Proffered Paper session 1" session.SAN DIEGO, Dec. 5, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company today announced preliminary results from the KR
Dec 02, 2022 07:00 am ET
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study
Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer with Acquired Resistance to Chemotherapy and Immune Checkpoint Inhibitor Therapy
Nov 28, 2022 07:00 am ET
Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO
SAN DIEGO, Nov. 28, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced a late-breaking presentation of concurrent combination results of adagrasib and pembrolizumab in first line advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Findings will be presented on December 7 at the 2022 European Society of Medical Oncology Immuno-Oncology (ESMO IO) Annual Congress as an oral presentation from 2:15 p.m.-2:25 p.m. CET / 8:15 a.m.-8:25 a.m. ET (Presentation #LBA4) during the "Proffered Paper ses
Nov 08, 2022 03:10 pm ET
Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates.
Nov 08, 2022 03:05 pm ET
Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team
Charles M. Baum, M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a decade of Mirati leadership, driving corporate transformation
Nov 07, 2022 08:15 am ET
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
Incyte (NASDAQ:INCY) and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced a clinical trial collaboration and supply agreement to investigate the combination of INCB99280, Incyte’s small molecule PD-L1 inhibitor, and adagrasib, a KRASG12C selective inhibitor.
Nov 02, 2022 04:15 pm ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 13 new employees with a grant date of November 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Oct 25, 2022 04:30 pm ET
Mirati Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Updates
SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2022 along with recent corporate updates on November 8, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on November 8, company executives will provide company updates and review financial results.
Oct 12, 2022 08:00 am ET
Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C
SAN DIEGO and LOS ANGELES, Oct. 12, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (Nasdaq: AADI), a commercial stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS G12C mutant non-small cell lung
Oct 05, 2022 04:30 pm ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 5, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 22 new employees with a grant date of October 3, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Sep 22, 2022 04:30 pm ET
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
SAN DIEGO, Sept. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.
Sep 07, 2022 06:05 pm ET
Mirati Therapeutics Presents Late-Breaking Adagrasib Monotherapy and Combination Results in Advanced Colorectal Cancer
Adagrasib demonstrates promising clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation
Sep 02, 2022 06:07 pm ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 25 new employees with a grant date of September 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 31, 2022 04:30 pm ET
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
SAN DIEGO, Aug. 31, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.
Aug 04, 2022 04:30 pm ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 4, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 56 new employees with a grant date of August 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 03, 2022 04:01 pm ET
Mirati Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter of 2022 and recent corporate updates.
Jul 20, 2022 04:30 pm ET
Mirati Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Updates
SAN DIEGO, July 20, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the second quarter of 2022 along with recent corporate updates on August 3, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on August 3, company executives will provide company updates and review financial results.
Jun 18, 2022 04:30 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 18, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors ofPTC Therapeutics, Inc. ("Mirati" or "the Company") (NASDAQ:MRTX) for violations of the securities laws.
Jun 16, 2022 09:58 am ET
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Mirati Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mirati Therapeutics, Inc. (“Mirati” or “the Company”) (NASDAQ:
Jun 07, 2022 09:31 am ET
Thinking about buying stock in Mirati Therapeutics, Buzzfeed, Charge Enterprises, Healthequity, or Academy Sports and Outdoors?
NEW YORK, June 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRTX, BZFD, CRGE, HQY, and ASO.
Jun 06, 2022 08:00 am ET
New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreat
Presentation marks first clinical dataset with a KRASG12C-inhibitor in patients with active, untreated CNS metastasesSAN DIEGO, June 6, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results of a prospective analysis from the Phase 1b cohort of the KRYSTAL-1 study evaluating intracranial (IC) responses of adagrasib in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) with active and untreated central nervous system (CNS) metastases. This is the first clinical data demonstrating CNS-specific activity o
May 26, 2022 05:00 pm ET
Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
SAN DIEGO, May 26, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID in patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy. Findings will be presented on June 3 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, as an oral presentation during the "Lung Cancer – Non-Small Cell Metastatic" session from
May 25, 2022 04:30 pm ET
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
SAN DIEGO, May 25, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.
May 19, 2022 04:30 pm ET
Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lun
Submission follows the U.S. FDA acceptance of the adagrasib New Drug Application for the same indication  
May 16, 2022 04:30 pm ET
Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
SAN DIEGO, May 16, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Laurie Stelzer as the Company's Chief Financial Officer (CFO) effective May 16, 2022. Laurie will report to the Company's Chief Executive Officer, David Meek.
May 04, 2022 04:01 pm ET
Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates
SAN DIEGO, May 4, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the first quarter of 2022 and recent corporate updates.
Apr 27, 2022 04:30 pm ET
Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib
Full results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib in patients with pre-treated non-small cell lung cancer (NSCLC) harboring a KRASG12C mutationLate-breaking data on adagrasib in patients with KRASG12C-mutated NSCLC with active and untreated central nervous system (CNS) metastasesCompany to host Virtual Investor Event on Monday, June 6, 2022 at 8 PM ET/7 PM CT to discuss highlights from ASCO 2022SAN DIEGO, April 27, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the
Apr 20, 2022 04:30 pm ET
Mirati Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Updates
SAN DIEGO, April 20, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the first quarter of 2022 along with recent corporate updates on May 4, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on May 4, company executives will provide company updates and review financial results.
Mar 02, 2022 03:30 pm ET
Mirati Therapeutics to Participate in the 42nd Annual Cowen Healthcare Conference
SAN DIEGO, March 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the 42nd Annual Cowen Healthcare Conference, which will be webcast on March 9 at 10:30 a.m. P.T. / 1:30 p.m. E.T. David Meek, chief executive officer, will represent the company.
Feb 28, 2022 03:01 pm ET
Mirati Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates
SAN DIEGO, Feb. 28, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year 2021 and recent corporate updates.
Feb 15, 2022 03:15 pm ET
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
SAN DIEGO, Feb. 15, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy. The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022.
Feb 14, 2022 06:30 am ET
Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2021 and Recent Corporate Updates on February 28, 2022
SAN DIEGO, Feb. 14, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the fourth quarter and full year of 2021 along with recent corporate updates on February 28, 2022. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on February 28, company executives will provide company updates and review financial results.
Feb 02, 2022 03:30 pm ET
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
SAN DIEGO, Feb. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.
Jan 21, 2022 09:00 am ET
Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers
SAN DIEGO, Jan. 21, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in patients with pretreated pancreatic ductal adenocarcinoma and other gastrointestinal (GI) tumors harboring a KRASG12C mutation, including cancers of the biliary tract, appendix, small bowel, gastro-esophageal junction, and esophagus. Results showed that adagrasib demonstrated significant clinical activity and broad disease control. The findings
Jan 04, 2022 03:30 pm ET
Mirati Therapeutics to Present at the J.P. Morgan 40th Annual Virtual Healthcare Conference
SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will present at the J.P. Morgan 40th Annual Virtual Healthcare Conference, on Monday, January 10, 2022. David Meek, chief executive officer, will make a formal presentation and answer questions about the Company at 2:15 p.m. P.T. / 5:15 p.m. E.T.
Dec 29, 2021 05:51 pm ET
Investigation Alert: Did You Lose Money on Your Stock? Johnson Fistel, LLP Encourages Investors to Contact the Firm
SAN DIEGO, Dec. 29, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP, is investigating potential claims against the following Companies for violations of federal securities laws.
Nov 23, 2021 03:30 pm ET
Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
SAN DIEGO, Nov. 23, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Evercore ISI HealthCONx Conference, which will be webcast on December 2 at 11:15 a.m. P.T. / 2:15 p.m. E.T. David Meek, chief executive officer and Charles Baum, M.D., Ph.D., president, founder and head of research and development, will represent the company.
Nov 22, 2021 07:30 am ET
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company and Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a non-exclusive clinical collaboration agreement to evaluate the combination of Mirati’s investigational KRASG12C inhibitor adagrasib with Verastem Oncology’s investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer (NSCLC).
Nov 22, 2021 06:30 am ET
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
SAN DIEGO and BOSTON, Nov. 22, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company and Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a non-exclusive clinical collaboration agreement to evaluate the combination of Mirati's investigational KRASG12C inhibitor adagrasib with Verastem Oncology's investigational RAF/MEK inhibitor VS-6766 in KRASG12C-mutant non-small cell lung cancer (NSCLC).
Nov 17, 2021 06:30 am ET
Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers
SAN DIEGO, Nov. 17, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the Company's synthetic lethal PRMT5 inhibitor, MRTX1719, for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers.
Nov 10, 2021 08:11 pm ET
Mirati Therapeutics Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Nov. 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, today announced the pricing of an underwritten public offering of 3,448,275  shares of its common stock at a price to the public of $145.00 per share. The aggregate gross proceeds to Mirati from this offering are expected to be approximately $500.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. The offering is expected to close on or about November 15, 2021, subject to customary closing conditions.
Nov 09, 2021 03:23 pm ET
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) a clinical-stage oncology company, today announced that it intends to offer and sell in an underwritten public offering $500 million of shares of its common stock. In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the total shares offered in the public offering at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether o
Nov 09, 2021 08:00 am ET
Mirati Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Stifel Healthcare Conference 2021, which will be webcast on November 16 at 8:20 a.m. P.T. / 11:20 a.m. E.T. David Meek, chief executive officer and Charles Baum, M.D., Ph.D., president, founder and head of research and development, will represent the company.
Nov 08, 2021 03:01 pm ET
Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
SAN DIEGO, Nov. 8, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2021 and recent corporate updates.
Nov 04, 2021 04:41 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirati Therapeutics, Inc. - MRTX
NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. ("Mirati" or the "Company") (NASDAQ: MRTX).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Nov 02, 2021 08:47 am ET
(MRTX) Alert: Did You Lose Money on Your Mirati Therapeutics Investment? Contact Johnson Fistel Regarding Investigation
SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Mirati Therapeutics, Inc. (NASDAQ: MRTX) for violations of federal securities laws.
Nov 01, 2021 04:30 pm ET
Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corporate Updates on November 8, 2021
SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2021 and recent corporate updates on Monday, November 8. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on November 8, company executives will provide company updates and review financial results.
Nov 01, 2021 02:05 pm ET
(MRTX) Alert: Did You Lose Money on Your Mirati Therapeutics Investment? Contact Johnson Fistel Regarding Investigation
Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Mirati Therapeutics, Inc. (NASDAQ: MRTX) for violations of federal securities laws. On November 1, 2021, Mirati, in an SEC filing, disclosed that certain...
Oct 07, 2021 04:30 pm ET
Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer
SAN DIEGO, Oct. 7, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of adagrasib, the Company's investigational KRASG12C inhibitor, with Sanofi's investigational SHP2 inhibitor SAR442720, also known as RMC-4630. The Phase 1/2 dose escalation and expansion study will evaluate the combination in patients with previously-treated non-small cell lung cancer (NSCLC) and KRASG12C mutations.   
Oct 04, 2021 04:30 pm ET
Mirati Therapeutics to Present New Research From its Innovative Oncology Pipeline at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer
SAN DIEGO, Oct. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced new clinical and preclinical research will be presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, taking place October 7 - 10, 2021.
Sep 24, 2021 04:15 pm ET
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 24, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that in connection with the hiring, announced on September 20, 2021, of David Meek as Chief Executive Officer, Mr. Meek received an inducement award to purchase up to 150,300 shares of common stock. The stock option has an exercise price per share of $167.10, the closing price of the Company's common stock on the Nasdaq Global Select Market on September 22, 2021 and will vest over four years, with 25% of the underlying shares vesting on the one-year
Sep 20, 2021 09:31 am ET
Thinking about trading options or stock in Mirati Therapeutics, Pfizer, Ligand Pharmaceuticals, Alibaba, or Equinix?
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRTX, PFE, LGND, BABA, and EQIX.
Sep 20, 2021 08:20 am ET
Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Check
SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500. Results showed durable responses and long-term survival with sitravatinib in combination with nivolumab (OPDIVO®)1 in patients with second or third line non-squamous non-small cell lung cancer (NSCLC) who experienced clinical benefit on a prior checkpoint inhibitor (CPI) and subsequent disease progression (n=68).
Sep 20, 2021 07:55 am ET
Mirati Therapeutics Appoints David Meek as Chief Executive Officer
SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of David Meek as Chief Executive Officer (CEO), effective immediately. Mr. Meek will also join the Company's Board of Directors. Charles M. Baum, M.D., Ph.D. will continue to lead the research and development (R&D) organization as president, founder and head of R&D. Dr. Baum will remain on the Company's Board of Directors.
Sep 20, 2021 07:30 am ET
Mirati Therapeutics Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive topline results from the potentially registration-enabling cohort of the Phase 2 KRYSTAL-1 study, evaluating adagrasib in patients with advanced non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation following prior systemic therapy. 
Sep 19, 2021 09:47 am ET
Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer
SAN DIEGO, Sept. 19, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation. Results showed that adagrasib alone and with cetuximab demonstrated significant clinical activity and broad disease control in these patients. The findings (Abstract # LBA6) will be presented today at 9:47 a.m. ET as
Sep 15, 2021 04:15 pm ET
Mirati Therapeutics to Host Virtual Investor Event on Monday, September 20, 2021
SAN DIEGO, Sept. 15, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will host a virtual Investor Event on Monday, September 20, 2021 at 8:30 a.m. ET / 5:30 a.m. PT.
Aug 25, 2021 04:30 pm ET
Mirati Therapeutics Clinical Research at ESMO Congress 2021 to Highlight Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers
SAN DIEGO, Aug. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced two oral presentations of clinical data will be presented at the upcoming European Society for Medical Oncology Congress (ESMO) 2021, reinforcing the clinical benefit of adagrasib, a KRASG12C inhibitor, and sitravatinib, a receptor tyrosine kinase inhibitor. The congress will take place virtually from September 16 to 21, 2021.
Aug 05, 2021 04:15 pm ET
Mirati Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Updates
SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter of 2021 and recent corporate updates.
Jun 24, 2021 04:42 pm ET
Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation
SAN DIEGO, June 24, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to adagrasib for the potential treatment of patients with non-small cell lung cancer (NSCLC) who harbor the KRASG12C mutation following prior systemic therapy.
Jun 01, 2021 07:30 am ET
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the companies have entered into a...
May 25, 2021 04:05 pm ET
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, Mirati’s invest
Feb 25, 2021 03:15 pm ET
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates
SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today reported financial results for the fourth quarter and full year of 2020, which reflect the company's progress across its clinical and discovery pipeline and strength as it expands its operational structure and capabilities in preparation for potential commercialization in the United States.
Feb 18, 2021 03:15 pm ET
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, will participate in two upcoming healthcare conferences.
Feb 10, 2021 06:00 am ET
MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors
HOUSTON and SAN DIEGO, Feb. 10, 2021 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS muta
Feb 04, 2021 03:30 pm ET
Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days
SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced they will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Days on Thursday, February 11th at 9:00 a.m. ET/6:00 a.m. PT. Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event.
Jan 04, 2021 04:19 pm ET
Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11th at 12:40 p.m. PST/ 3:40 p.m. EST. Charles M. Baum, M.D., Ph.D., Mirati's President and Chief Executive Officer will present at the conference.
Nov 23, 2020 03:30 pm ET
Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference
SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2020 Evercore ISI HealthCONx Conference on Tuesday, December 1st at 8:20 a.m. PT/11:20 a.m. ET. Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event.
Nov 05, 2020 03:30 pm ET
Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Thursday, November 12, 2020 at 9:30 a.m. PT/12:30 p.m. ET. Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event.
Nov 04, 2020 03:15 pm ET
Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights
SAN DIEGO, Nov. 4, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights.
Oct 30, 2020 05:09 pm ET
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
SAN DIEGO, Oct. 30, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common stock at a public offering price of $202.00 per share, which consists of 4,585,706 shares sold by Mirati and 400,000 shares sold by a selling stockholder. This includes the exercise in full by the underwriters of their option to purchase up to 625,309 additional shares of common stock from Mirati and up to 25,000 additional shares of common stock from the selling stockholder. The aggregate g
Oct 27, 2020 08:04 pm ET
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00 per share, which consists of 3,960,397 shares to be sold by Mirati and 375,000 shares to be sold by a selling stockholder. The aggregate gross proceeds to Mirati from this offering are expected to be approximately $800.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. The offering is expected to close on or
Oct 26, 2020 04:46 pm ET
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Oct. 26, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell in an underwritten public offering $700.0 million of shares of its common stock and a selling stockholder intends to offer 375,000 shares in the offering. In addition, Mirati and the selling stockholder expect to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the total shares offered in the public offering at the public offering price, less the underwriting discounts and commissions. Mirati will not receive any proc
Oct 25, 2020 10:45 am ET
Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data
SAN DIEGO, Oct. 25, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced preliminary results from the Company's mutant KRAS selective inhibitor programs. The preliminary results included updated clinical data of adagrasib (MRTX849), the Company's KRAS G12C inhibitor, presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutics ("ENA") and initial preclinical in vivo data of MRTX1133, the Company's selective and potent potential first-in-class KRAS G12D inhibitor.
Oct 15, 2020 04:30 pm ET
Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)
SAN DIEGO, Oct. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical data from adagrasib (MRTX849), the Company's KRAS G12C selective inhibitor, will be presented at the EORTC-NCI-AACR International Virtual Conference on Molecular Targets and Therapeutics on October 25, 2020. Mirati will host an investor event following the presentations, which will include highlights from the conference as well as an update on MRTX1133, the Company's KRAS G12D selective inhibitor.
Oct 14, 2020 04:06 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Mirati Therapeutics, Inc. (“Mirati” or “the Company”) (NASDAQ:
Oct 06, 2020 02:55 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Mirati Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Mirati Therapeutics, Inc. (“Mirati” or “the Company”) (NASDAQ:
Aug 06, 2020 04:15 pm ET
Mirati Therapeutics Reports Second Quarter 2020 Financial Results And Recent Business Highlights
SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the second quarter ended June 30, 2020.
Aug 05, 2020 04:05 pm ET
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced it has entered into an exclusive worldwide license agreement with...
Jul 06, 2020 04:52 pm ET
MRTX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Mirati Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, July 6, 2020 /PRNewswire/ --Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mirati Therapeutics, Inc. ("Mirati" or the "Company") (NASDAQ: MRTX). Investors who purchased Mirati securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mrtx.                      
Jun 05, 2020 09:00 am ET
Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference
SAN DIEGO, June 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the upcoming 41st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer at Mirati will represent the Company during the fireside chat at 1:20 p.m. EDT/ 10:20 a.m. PDT.
May 18, 2020 04:15 pm ET
Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer
SAN DIEGO, May 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that Joseph Leveque, M.D. has been named Chief Medical Officer effective May 18, 2020. Isan Chen, M.D., will step down as Chief Medical and Development Officer to lead an early-stage biotech company, however, Dr. Chen will continue to act as an advisor to Mirati.
May 15, 2020 09:00 am ET
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II
SAN DIEGO, May 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the Company's pipeline of novel therapeutics in three presentations at the American Association for Cancer Research Virtual Annual Meeting II, taking place June 22-24, 2020. The data to be presented will include preclinical findings on MRTX849, a novel and optimized KRAS G12C inhibitor.
May 07, 2020 04:05 pm ET
Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates
SAN DIEGO, May 7, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the first quarter ended March 31, 2020.
Apr 20, 2020 07:23 am ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Mirati Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, April 20, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Mirati Therapeutics, Inc. (NASDAQ: MRTX).
Apr 20, 2020 07:00 am ET
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Mirati Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims
Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Mirati Therapeutics, Inc. (NASDAQ: MRTX). If you are a shareholder of Mirati Therapeutics, Inc. and wish to receive...
Dec 13, 2019 07:00 am ET
BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and Mirati Therapeutics...
Nov 09, 2019 05:15 pm ET
Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting
SAN DIEGO, Nov. 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in metastatic urothelial cancer (mUC) patients with documented progression on a platinum-chemotherapy and checkpoint inhibitor. The data were presented in an oral presentation at the Society of Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, MD. Preliminary results from the ongoing Phase 1 study of neoa
Nov 04, 2019 03:15 pm ET
Mirati Therapeutics Reports Third Quarter 2019 Financial Results
SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2019.
Oct 28, 2019 04:15 pm ET
Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the first clinical results from its Phase 1/2 trial evaluating MRTX849, an investigational KRAS G12C inhibitor, in patients with solid tumors expressing KRAS G12C mutations. MRTX849 demonstrated clinical activity, including objective responses, in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). While the maximum tolerated dose (MTD) has not yet been established, dose expansion is underway, and the trial continues to enrol
Oct 23, 2019 04:45 pm ET
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib Data In Urothelial Carcinoma And Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
SAN DIEGO, Oct. 23, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that the Company will have two presentations at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting on November 6-10, 2019 at the Gaylord National Convention Center in National Harbor, MD.
Oct 17, 2019 09:00 am ET
Mirati Therapeutics To Present Pre-Clinical And Initial Clinical Data For MRTX849, A KRAS G12C Inhibitor, At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeuti
SAN DIEGO, Oct. 17, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present pre-clinical data and initial clinical data on MRTX849, a novel and optimized KRAS G12C inhibitor, in presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, October 26-30, 2019 at the Hynes Convention Center.
Aug 15, 2019 04:30 pm ET
Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources
SAN DIEGO, Aug. 15, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced the appointment of Jenny Gizzi as Vice President, Human Resources, reporting directly to Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer.
Aug 05, 2019 04:15 pm ET
Mirati Therapeutics Reports Second Quarter 2019 Financial Results
SAN DIEGO, Aug. 5, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2019.
Jul 09, 2019 04:30 pm ET
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
SAN DIEGO, July 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati's investigational KRAS G12C inhibitor and TNO155, Novartis' investigational SHP2 inhibitor, in patients with advanced solid tumors that harbor KRAS G12C mutations.
Jul 01, 2019 04:30 pm ET
Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors
SAN DIEGO, July 1, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Dr. Julie Cherrington, Ph.D. to its Board of Directors, effective June 27, 2019. Dr. Cherrington has extensive experience in oncology drug development and has played a key role in the development of several FDA-approved products.
Apr 29, 2019 04:05 pm ET
Mirati Therapeutics Reports First Quarter 2019 Financial Results
SAN DIEGO, April 29, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the first quarter ended March 31, 2019.
Apr 01, 2019 04:30 pm ET
Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference
SAN DIEGO, April 1, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London, England on Monday, April 8th at 11:30am BST/6:30am ET/3:30am PT. Christopher C. LeMasters, Chief Business Officer, will provide a corporate update at the conference.
Mar 05, 2019 03:30 pm ET
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
SAN DIEGO, March 5, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at two upcoming healthcare conferences.
Feb 28, 2019 03:15 pm ET
Mirati Therapeutics Reports Fourth Quarter Financial Results
SAN DIEGO, Feb. 28, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full-year ended December 31, 2018.
Feb 25, 2019 08:10 am ET
Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Biogen Inc. (NASDAQ:BIIB), Mirati Therapeutics, Inc. (NASDAQ:MRTX),...
Feb 19, 2019 03:15 pm ET
Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors
SAN DIEGO, Feb. 19, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Faheem Hasnain as Chairman of the Board, effective February 15, 2019. Dr. Rodney Lappe Ph.D. is retiring from the board and his role as Chairman and will not seek re-election at the Company's 2019 annual meeting of shareholders. Dr. Lappe has provided leadership and guidance to the Company over the last eight years and has served with distinction as Chair for the last five years. We anticipate that Dr. Lappe will continue to serve t
Feb 07, 2019 03:30 pm ET
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14th at 11:00 a.m. ET/ 8:00 a.m. PT. Chris LeMasters, Chief Business Officer and James Christensen, Chief Scientific Officer will provide a corporate overview during a fireside chat at the conference.
Jan 22, 2019 03:01 pm ET
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
SAN DIEGO, Jan. 22, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 1,854,838 shares of its common stock at a public offering price of $62.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 241,935 additional shares of common stock. The aggregate gross proceeds to Mirati from this offering were approximately $115.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. 
Jan 16, 2019 07:45 pm ET
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. The offering is expected to close on or about January 22, 2019, subject to customary closing conditions. Mirati has also granted the underwriters a 30-day option t
Jan 16, 2019 03:01 pm ET
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, $75.0 million of shares of its common stock in an underwritten public offering. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares are being offered by Mirati. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Jan 15, 2019 03:21 pm ET
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
SAN DIEGO, Jan. 15, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid tumors that harbor KRAS G12C mutations.
Jan 07, 2019 07:30 am ET
Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
SAN DIEGO, Jan. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) a clinical-stage targeted oncology company, today announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and nivolumab (OPDIVO®), in Mirati's planned Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.
Jan 02, 2019 03:30 pm ET
Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 2, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9th at 8:00 a.m. PST/ 11:00 a.m. EST. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will provide a corporate update at the conference.
Dec 20, 2018 03:42 pm ET
Mirati Therapeutics Added To NASDAQ Biotechnology Index
SAN DIEGO, Dec. 20, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: ^NBI). The Company's addition to the Index will become effective prior to market open on Monday, December 24, 2018.
Dec 10, 2018 03:15 pm ET
Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors
SAN DIEGO, Dec. 10, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Maya Martinez-Davis to the Company's Board of Directors, effective immediately.
Dec 04, 2018 07:20 am ET
Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mirati Therapeutics, Inc. (NASDAQ:MRTX), comScore, Inc. (NASDAQ:SCOR),...
Nov 29, 2018 04:20 pm ET
Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849
SAN DIEGO, Nov. 29, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for MRTX849, a small molecule inhibitor of KRAS G12C.  Mirati is developing MRTX849 for the treatment of cancers driven by KRAS G12C mutations. 
Nov 20, 2018 03:30 pm ET
Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 20, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27th at 12:30 p.m. EST/ 9:30 a.m. PST. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will represent Mirati at the conference.
Nov 09, 2018 07:35 am ET
Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. The data will be presented today in a poster and also in an oral presentation on Saturday, November 10th.
Nov 09, 2018 07:30 am ET
Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. The data will be presented today in a poster and also in an oral presentation on Sunday, November 11th.
Nov 08, 2018 03:32 pm ET
Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors
SAN DIEGO, Nov. 8, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced dosing of the first patient under its collaboration agreement with BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) in a Phase 1b clinical trial to assess the safety and tolerability, pharmacokinetics and preliminary anti-tumor activity of Mirati's sitravatinib in combination with BeiGene's investigational anti-PD1 antibody, tislelizumab, in patients with advanced solid tumors. The clinical trial is currently enrolling patients in China and Australia.
Nov 07, 2018 08:00 am ET
Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference
SAN DIEGO, Nov. 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 27th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 14th at 1:40 p.m. MST/ 12:40 p.m. PST. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will present a corporate overview at the conference.
Nov 06, 2018 03:15 pm ET
Mirati Therapeutics Reports Third Quarter Financial Results
SAN DIEGO, Nov. 6, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2018.
Nov 05, 2018 03:15 pm ET
Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 5, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that the Company will have two oral presentations at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting to be held November 9-11, 2018 in Washington, D.C. Preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in non-small cell cancer lung (NSCLC) patients will be presented along with a data update in the ongoing Phase 2 clinical trial of mocetinostat in combination with durv
Oct 30, 2018 09:00 am ET
Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer
SAN DIEGO, Oct. 30, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2 trial with the initial goal to evaluate safety, tolerability and pharmacokinetics of the Company's KRAS G12C inhibitor, MRTX849, in patients with advanced solid tumors. The trial will utilize an accelerated titration design with single patient cohorts and intra-patient dose escalation to rapidly achieve an active
Oct 25, 2018 08:50 am ET
Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook — Fundamental Analysis, Calculating Forward Move
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CSG Systems International, Inc. (NASDAQ:CSGS), Zumiez Inc....
Oct 22, 2018 06:10 am ET
Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial
SAN DIEGO, Oct. 22, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of updated data from its ongoing Phase 2 clinical trial of sitravatinib in combination with OPDIVO® (nivolumab) in non-small cell lung cancer (NSCLC) patients with documented progression on prior immune checkpoint inhibitor therapy. The data were presented today in a Proffered Paper Session (oral presentation) at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.  
Oct 21, 2018 05:10 am ET
Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress
SAN DIEGO, Oct. 21, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the completed stage 1 safety and efficacy data from the ongoing Phase 1b clinical trial of single agent sitravatinib in patients with certain classes of oncogenic mutations. The data for a cohort of patients harboring CBL mutations were presented in a proffered poster session (oral presentation) on Sunday, October 21st, 2018, at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.
Oct 15, 2018 04:30 pm ET
Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call
SAN DIEGO, Oct. 15, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that in conjunction with the two Proffered Papers Sessions (oral presentations) highlighting data from ongoing clinical trials of sitravatinib, the Company will conduct an investor conference call during the 2018 Annual Meeting of the European Society for Medical Oncology in Munich, Germany, on October 22nd at 2:00 p.m. CEST/8:00 a.m. EDT/5:00 a.m. PDT.
Aug 29, 2018 04:30 pm ET
Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference
SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in two panel discussions, at the 2018 Citi Biotech Conference in Boston. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will represent Mirati at the event.
Aug 16, 2018 04:30 pm ET
Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
SAN DIEGO, Aug. 16, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced that a KRAS G12C poster will be presented by scientists from Mirati and Array BioPharma at the 255th American Chemical Society (ACS) National Meeting & Exposition being held in Boston, MA, August 19-23, 2018. The poster will focus on the discovery and preclinical characterization of covalent inhibitors of KRAS G12C that have demonstrated potent pathway inhibition in cells and efficacy in tumor xenograft models.
Aug 01, 2018 04:15 pm ET
Mirati Therapeutics Reports Second Quarter Financial Results
SAN DIEGO, Aug. 1, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2018.
Jul 24, 2018 04:59 pm ET
Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress
SAN DIEGO, July 24, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that two abstracts highlighting data from ongoing clinical studies of sitravatinib will be presented as Proffered Papers in oral presentations at the 2018 Annual Meeting of the European Society for Medical Oncology October 19-23 in Munich, Germany.
Jun 25, 2018 04:30 pm ET
Mirati Therapeutics Added to Russell 2000® Index
SAN DIEGO, June 25, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been added to the Russell 2000® Index, effective as of the open of the market on Monday, June 25, 2018, following Russell's annual reconstitution of its comprehensive set of U.S. and global equity indexes.
Jun 11, 2018 04:15 pm ET
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, June 11, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 3,162,500 shares of its common stock at a public offering price of $38.85 per share representing no discount to the last closing price of its common stock immediately preceding the announcement of the offering. This includes the exercise in full by the underwriters of their option to purchase up to 412,500 additional shares of common stock. In addition, and in lieu of common stock, Mirati sold to certain investors pre-funded
Jun 07, 2018 08:00 am ET
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO, June 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 2,750,000 shares of its common stock at a price to the public of $38.85 per share. In addition, and in lieu of common stock, Mirati is offering to certain investors pre-funded warrants to purchase up to an aggregate of 421,650 shares of common stock at a purchase price of $38.849 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggr
Jun 06, 2018 04:01 pm ET
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 6, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares are being offered by Mirati. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
May 31, 2018 04:30 pm ET
Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting
SAN DIEGO, May 31, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that new data from the ongoing Phase 1b clinical trial of single agent sitravatinib will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 1-5, 2018 in Chicago. The data will highlight initial results from the cohort evaluating sitravatinib in the treatment of patients with metastatic renal cell carcinoma (mRCC) who are refractory to anti-angiogenic therapy.
May 07, 2018 04:10 pm ET
Mirati Therapeutics Reports First Quarter Financial Results
SAN DIEGO, May 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company, today reported financial results for the first quarter ended March 31, 2018.
Apr 24, 2018 04:15 pm ET
Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
SAN DIEGO, April 24, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) (the Company or Mirati), a clinical-stage targeted oncology company, today provided a progress update on its lead development programs and announced updated, positive clinical trial data for sitravatinib, a spectrum selective kinase inhibitor, and mocetinostat, a class I and IV HDAC inhibitor. The Company has been evaluating sitravatinib and mocetinostat in separate Phase 2 clinical trials in combination with checkpoint inhibitor therapy in non-small cell lung cancer (NSCLC) patients whose disease had progress
Mar 08, 2018 03:30 pm ET
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results
SAN DIEGO, March 8, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, today reported financial results for the fourth quarter and full-year ended December 31, 2017.
Mar 07, 2018 03:30 pm ET
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
SAN DIEGO, March 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at three upcoming healthcare conferences.
Feb 21, 2018 07:35 am ET
Recent Analysis Shows EchoStar, Toro, Genesee & Wyoming, Express Scripts Holding, D.R. Horton, and Mirati Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EchoStar Corporation (NASDAQ:SATS), Toro Company (NYSE:TTC),...
Feb 08, 2018 03:15 pm ET
Mirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference
SAN DIEGO, Feb. 8, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will participate in the Leerink Partners 7th Annual Global Healthcare Conference in New York on Thursday, February 15th at 2:30 p.m. ET/ 11:30 a.m. PT. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will provide a corporate overview during a fireside chat presentation at the conference.
Jan 08, 2018 06:00 am ET
BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region
CAMBRIDGE, Mass. and BEIJING, China and SAN DIEGO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, and...
Dec 05, 2017 05:00 am ET
New Research: Key Drivers of Growth for Express Scripts Holding, D.R. Horton, Mirati Therapeutics, EchoStar, Toro, and Genesee & Wyoming — Factors of Influence, Major Initiatives and Sustained Product
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Express Scripts Holding Company (NASDAQ:ESRX), D.R....
Nov 20, 2017 04:15 pm ET
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 2,938,986 shares of its common stock at a public offering price of $13.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 923,085 additional shares of common stock. In addition, and in lieu of common stock, Mirati sold to certain investors pre-funded warrants to purchase up to an aggregate of 4,137,999 shares of common stock at a purchase price of $12.999 per warrant, which

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More